INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
← catalyst calendarNCT06314282 · readout in 499 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
32
Countries
Argentina, China, Costa Rica +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-22 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus (SLE)
Primary outcomes
what the primary-completion date above is the date OFPGA
measured Baseline (pre-infusion) Month 1, Month 3, Month 6, Month 12
SLEDAI-2K
measured Baseline (pre-infusion) Month 1, Month 3, Month 6, Month 12
CLASI
measured Baseline (pre-infusion) Month 1, Month 3, Month 6, Month 12
FACIT-Fatigue
measured Baseline (pre-infusion) Month 1, Month 3, Month 6, Month 12
LupusQoL
measured Baseline (pre-infusion) Month 3, Month 6, Month 12
EQ-5D-5L
measured Baseline (pre-infusion) Month 3, Month 6, Month 12
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed